REVOLAX SUB-Q Lidocaine 1x 1,1ml

REVOLAX SUB-Q contains 24 mg/ml of highly purified, monophasic hyaluronic acid combined with 0.3 % lidocaine for added comfort. Its advanced cross-linking process stabilizes HA chains while removing residual agents to extremely low levels, making it biocompatible and safe for patients.

The gel's high elasticity (around 280 Pa G′) offers excellent structural support for facial shaping, while remaining smooth enough to pass through a 25 G needle easily. The formula retains much of its firmness even after months in the body, supporting results that last 12 to 18 months.

Lidocaine is mixed during production for even distribution, minimizing injection discomfort. The phosphate-buffered carrier keeps pH near 7, helping reduce swelling and inflammation after treatment.

This combination of dense HA and low endotoxin content supports rapid integration with surrounding tissue, minimizing lumpiness and ensuring a natural-looking contour. sample

REVOLAX SUB-Q is designed for structural facial augmentation—not just line filling. It’s ideal for reshaping jawlines, building chin projection, and performing non-surgical rhinoplasty, where solid support is needed rather than superficial hydration.

Best suited for patients with moderate to severe volume loss or those looking for sharper facial definition, especially when skin thickness supports deep placement.

Compared to REVOLAX Deep, SUB-Q has higher elasticity and retains its shape better under movement, making it perfect for jawline sculpting, chin enhancement, and dorsal nose augmentation.

It also performs well in combination treatments, such as layering beneath threads or after deoxycholic acid lipolysis. Standard contraindications apply, including pregnancy, active skin conditions, autoimmune flares, and hypersensitivity to ingredients. s

Each REVOLAX SUB-Q box includes:

1 x 1.1 ml prefilled glass syringe with secure Luer-Lock hub

2 x 25 G 13 mm ultra-thin-wall sterile needles

2 traceability labels for patient records and clinic logs

Instructions for Use booklet detailing recommended injection techniques

Packaging is tamper-evident and designed for safety, with an oxygen absorber to maintain HA quality and a three-year shelf life when stored between 2 °C and 25 °C.

Clinical results show around 70 % of volume retention at 12 months and over 50 % at 18 months following single-session treatments for jawline contouring. Patient satisfaction rates remain high at one year, with many reporting maintained definition and lift. Longevity depends on injection depth and area: periosteal deposits under the cheekbone last longest, while highly mobile areas like the mouth may see faster resorption. Factors like smoking and high activity levels can reduce duration, but touch-ups at 9–12 months help maintain results. The gel is fully dissolvable with hyaluronidase even after long-term placement, allowing safe corrections if needed.

Q1: Is REVOLAX SUB-Q CE-marked or FDA-cleared?
A1: It holds a Class III CE mark for professional use in Europe. It is not FDA-approved for use in the U.S.

Q2: How painful is the treatment?
A2: Pain is mild. Integrated 0.3 % lidocaine and the use of a 25 G thin-wall needle keep discomfort very low, often eliminating the need for topical numbing.

Q3: Can the filler migrate or form lumps?
A3: The cohesive gel structure minimizes migration. Any small nodules usually respond well to massage or can be dissolved with hyaluronidase if necessary.

REVOLAX

REVOLAX is produced by ACROSS Co. Ltd., a South Korean company known for advanced HA filler manufacturing under ISO 13485 and 14001 standards. Production facilities use closed-system fermentation for ultra-pure HA and renewable energy for sustainability.

Each batch undergoes strict quality control, including endotoxin and particulate testing. While FDA approval is pending, ACROSS continues to support research and clinical trials to meet international standards.

Beyond manufacturing, ACROSS invests in dermatology research and sustainability initiatives like forest restoration partnerships, reflecting its commitment to ethical production and patient safety.